Harvard Bioscience, Inc.
HBIOHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHarvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. At a $36.2M market cap, Harvard Bioscience, Inc. ranks as a micro-cap company within healthcare. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
Market Cap
$36.2M
Beta
1.53
P/E (TTM)
—
P/E (Fwd)
12.33
EPS (TTM)
$-2.29
EPS (Fwd)
$0.65
ROE
-90.0%
ROA
1.6%
Cash
$6.5M
Total Debt
$44.2M
Free CF
$5.3M
52W Change
78.2%
Annual Financials
Cash vs Debt
Where HBIO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, HBIO finished 36.89% above its 150-day moving average ($5.99) and 32.69% above its 200-day moving average ($6.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HBIO overbought or oversold?
At the September 3, 2026 close, HBIO's RSI(14) was 85.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, HBIO has $6.5M in cash with $44.2M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $5.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -90.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.6% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $118.9M (2021) to $86.5M (2025), a 27% decline worth watching.
A beta of 1.53 means HBIO is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Harvard Bioscience, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing HBIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.